ANEW MEDICAL, INC. is dedicated to realizing the potential of biologic, cell and gene therapies to offer transformative patient outcomes in areas of high unmet medical need by extending the reach of protein, cell, and gene therapies to highly prevalent neurodegenerative disorders like amyotrophic lateral sclerosis (ALS) and Alzheimer’s disease as they are universally fatal neurodegenerative diseases.
Our vision is to build a leading gene therapy company for the treatment of neurodegenerative diseases and cancer by progressing our á-Klotho gene therapy research programs and identifying, developing, and commercializing other novel gene therapy treatments and in vitro diagnostics for neurodegenerative diseases, cancer and other age-related pathologies.
We have assembled a portfolio of gene therapy candidates in partnership with leading scientific institutions and have built a team with extensive experience in the biotechnology commercialization and gene therapy space. Our team will pursue new innovations in vector design and delivery to optimize our investigational gene therapy products for safety, potency, durability, and clinical response. We plan on building integrated internal development capabilities from product development through commercialization and focus on accelerating the pace of product development in the clinic. In addition, as part of our ongoing business strategy, we continue to explore potential opportunities to acquire or license new product candidates as well as opportunities for partnership or collaboration on our existing products in development.
There are currently two licensed platform technologies managed by our team — (1) A cell therapy and gene therapy platform that uses a gene therapy approach to introduce a human gene that produces a therapeutic protein called “Klotho” inside the body to treat neurodegenerative diseases and other diseases of aging, and (2). A proprietary, patented technology platform with a library of melanocortin receptor-binding molecules.
In addition to these two platform technologies, the company has also acquired a portfolio of “generic” drugs and “biosimilar” biologics that will allow us to sell hard-to-source, difficult to find generic oncology drugs and off-patent biologic therapies.
In pursuing our mission of developing therapeutic agents based on the human á-Klotho gene, we will initially focus on the development of a diagnostic test to to measure the various isoforms and metabolic products of α-Klotho in the body fluids of humans. This will be of value to Anew both in terms of identifying suitable patients for inclusion in our future clinical trials, and also as a potential near term revenue generator.
We believe that there is currently limited competition in our pursuit of the diagnostic and therapeutic potential of the human á-Klotho gene due to our strong intellectual property position and technology know-how. Thus, our portfolio of gene therapy candidates targets a broad spectrum of indications across many age-related diseases, and potentially “aging” itself.
In summary, ANEW was founded to develop and provide disruptive new therapies to alleviate and/or reverse the progression of cancer and neurodegenerative diseases through the use of cell and gene therapy. Our goal is to develop innovative treatments for people with cancer, Alzheimer’s, Parkinson’s disease, and amyotrophic lateral sclerosis (“ALS” or “Lou Gehrig’s Disease”).